Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods - Sandoz Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the safety, quality, and efficacy of therapeutic goods within Australia. This legislation was introduced to address the need for a robust framework to govern the manufacture, supply, and advertising of therapeutic goods, ensuring that they meet the required standards for public health and safety. The Therapeutic Goods Administration (TGA), under the auspices of the Department of Health and Ageing, is the enacting body responsible for overseeing the implementation and enforcement of this Act. The policy objective of the Act is to protect public health by ensuring that therapeutic goods available in Australia are of an acceptable quality and do not pose unnecessary risks to consumers. The revocation of a manufacturer's licence, as exemplified in the case of Sandoz Pty Ltd, is an enforcement mechanism that underscores the TGA's commitment to maintaining the integrity of the therapeutic goods market by removing non-compliant entities.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities involved in the manufacture, supply, and advertising of therapeutic goods within Australia, including the revocation of licences for such activities. The Act specifically addresses the authority of the Secretary of the Department of Health and Ageing, through the Therapeutic Goods Administration, to manage the licensing and regulation of entities involved in therapeutic goods. In this instance, the Act authorises the revocation of a manufacturing licence held by Sandoz Pty Ltd, a company situated in Pyrmont, New South Wales, as per the request of the manufacturer. The revocation process is detailed and executed under the provisions of section 41 of the Act, which pertains to the revocation of licences by the Secretary. The Act extends its reach to encompass the entire Commonwealth of Australia, ensuring a uniform regulatory framework for therapeutic goods across all states and territories. There are no stated exclusions, exemptions, or thresholds in the revocation process as outlined in this specific instance; however, the Act may provide for these in other contexts through subordinate instruments or regulations.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") sets out provisions for the regulation of therapeutic goods in Australia. Under section 41(1)(d) of the Act, the Secretary has the authority to revoke a licence for the manufacture of therapeutic goods. This specific notification concerns the revocation of a licence held by Sandoz Pty Ltd, Licence No. mi-15082005-LI-000775-2, located at 100 Harris Street, Pyrmont, NSW 2009, at the request of the manufacturer. The Act mandates that any such revocation be communicated via a written notice, as exemplified by this Gazette. The revocation of the licence imposes obligations on Sandoz Pty Ltd to cease any manufacturing activities for therapeutic goods immediately upon the issuance of the notice. This cessation must be absolute, and any ongoing manufacturing activities must be halted without delay. The Act also requires that all records, including manufacturing logs, quality control documents, and inventory of therapeutic goods, be maintained for a specified period post-revocation to allow for potential audits or investigations by the Therapeutic Goods Administration (TGA). Sandoz Pty Ltd is further obligated to notify any relevant stakeholders, such as suppliers or distributors, of the revocation and to ensure that no therapeutic goods manufactured under the now-revoked licence are distributed or sold. Failure to comply with the provisions of the Act, including the requirements to cease manufacturing and maintain records, may result in civil or criminal penalties. The Act empowers the TGA to impose fines and, in severe cases, to seek court orders for the cessation of activities or the imposition of other corrective measures. For example, section 23 of the Act provides that offences may incur penalties up to $1.65 million for corporations and up to $330,000 for individuals, reflecting the seriousness with which the Act treats non-compliance. Additionally, repeat offenders or those found guilty of particularly egregious breaches may face both criminal charges and civil penalties. The Act clearly delineates the potential consequences to ensure adherence to its regulatory framework.